ViroCyt launches new product to purify viruses

ViroCyt, LLC, a Denver-based life science company, announced the launch on Tuesday of a rapid virus cleanup system meant to purify viruses in egg- and cell-based systems.

ViroPrep Plus is a spin column-based clean-up method that can be used to replace time-consuming and labor-intensive purification protocols during viral vaccine research, development and manufacturing, the creation of therapeutic proteins and new vaccine modalities, the generation of genetically-engineered viruses and when determining the potency of antivirals.

"We identified a clear and immediate need for a quick, straightforward system for removing background components such as protein, nucleic acid and cell debris, leaving a purified virus sample ready for immediate analysis," Robert Kline, President and CEO of ViroCyt, said. "The resulting ViroPrep Plus product directly addresses the demand we saw in the marketplace."

ViroPrep Plus is able to process up to 12 samples in less than an hour. Medigen, Inc., a biomedical company, beta tested the system and found the product intuitive and effective.

"We were fortunate enough to beta-test the ViroPrep Plus system, using it to purify influenza from allantoic fluid, which is arguably one of the most complex and challenging environments to isolate viruses from," Peter Pushko, the president of Medigen, Inc., said. "We found the product to be very easy to use, taking less than an hour. The kit eliminates background from the samples to almost undetectable levels, and we observed only small loss of virus particles."

ViroCyt is primarily focused on replacing outdated technologies that can slow down virus-related research and product development.